Entera Bio ( (ENTX) ) has provided an update.
On March 16, 2025, Entera Bio Ltd. entered into a collaboration and license agreement with OPKO Health, Inc. and OPKO Biologics Ltd. to develop an oral dual agonist GLP-1/glucagon peptide for treating obesity, metabolic, and fibrotic disorders. Under the agreement, Entera and OPKO will share development costs and proceeds, with Entera holding a 40% stake and OPKO 60%. Entera issued shares to OPKO to fund its share of development costs, and the collaboration aims to advance the first oral GLP-1/glucagon dual agonist into clinical trials, potentially impacting the treatment landscape for related disorders.
More about Entera Bio
Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs. The company leverages its proprietary N-Tab™ technology platform and has a pipeline that includes first-in-class oral peptide programs targeting various disorders. Entera’s most advanced product candidate is EB613, an oral treatment for osteoporosis, and the company is also developing oral treatments for obesity and other conditions.
YTD Price Performance: -16.44%
Average Trading Volume: 123,543
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $69.24M
See more data about ENTX stock on TipRanks’ Stock Analysis page.